08:03 AM EDT, 07/10/2025 (MT Newswires) -- Cognition Therapeutics ( CGTX ) said Thursday that it met with the US Food and Drug Administration to review results from the phase 2 study of zervimesine.

The parties Wednesday also discussed plans for a phase 3 program to support a new drug application for zervimesine as a treatment for Alzheimer's disease, Cognition Therapeutics ( CGTX ) said.

The company's shares were up past 45% in Thursday premarket activity.